BioNote Inc.
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-… Read more
BioNote Inc. (377740) - Total Assets
Latest total assets as of March 2023: ₩1.73 Trillion KRW
Based on the latest financial reports, BioNote Inc. (377740) holds total assets worth ₩1.73 Trillion KRW as of March 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioNote Inc. - Total Assets Trend (2019–2022)
This chart illustrates how BioNote Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BioNote Inc. - Asset Composition Analysis
Current Asset Composition (December 2022)
BioNote Inc.'s total assets of ₩1.73 Trillion consist of 47.0% current assets and 53.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 38.8% |
| Accounts Receivable | ₩16.37 Billion | 0.9% |
| Inventory | ₩79.04 Billion | 4.5% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩1.59 Billion | 0.1% |
| Goodwill | ₩5.51 Billion | 0.3% |
Asset Composition Trend (2019–2022)
This chart illustrates how BioNote Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioNote Inc.'s current assets represent 47.0% of total assets in 2022, an increase from 18.8% in 2019.
- Cash Position: Cash and equivalents constituted 38.8% of total assets in 2022, up from 5.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 4.5% of total assets.
BioNote Inc. Competitors by Total Assets
Key competitors of BioNote Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
BioNote Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BioNote Inc. generates 0.27x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, BioNote Inc. generates $ 17.52 in net profit.
BioNote Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.24 | 4.24 | 4.24 |
| Quick Ratio | 8.28 | 3.91 | 3.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩721.48 Billion | ₩ 599.11 Billion | ₩ 599.11 Billion |
BioNote Inc. - Advanced Valuation Insights
This section examines the relationship between BioNote Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.33 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 18.4% |
| Total Assets | ₩1.76 Trillion |
| Market Capitalization | $52.17 Million USD |
Valuation Analysis
Below Book Valuation: The market values BioNote Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: BioNote Inc.'s assets grew by 18.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BioNote Inc. (2019–2022)
The table below shows the annual total assets of BioNote Inc. from 2019 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | ₩1.76 Trillion | +18.45% |
| 2021-12-31 | ₩1.48 Trillion | +73.81% |
| 2020-12-31 | ₩853.44 Billion | +552.32% |
| 2019-12-31 | ₩130.83 Billion | -- |